Understanding DYNC2LI1: A Potential Drug Target and Biomarker

Target Name: DYNC2LI1

NCBI ID: G51626

DYNC2LI1

Understanding DYNC2LI1: A Potential Drug Target and Biomarker

DYNC2LI1 (CGI-60) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the DYNC family of proteins, which are known for their role in cell-cell adhesion and migration. In recent years, researchers have become interested in studying DYNC2LI1 as a potential drug target or biomarker due to its unique structure and its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The DYNC family of proteins was first identified in the late 1990s by researchers at the University of California, San Diego. The proteins in the family are characterized by the presence of a unique transmembrane domain and a unique intracellular domain that is involved in protein-protein interactions. The transmembrane domain is responsible for the protein's ability to interact with other proteins on the same membrane, while the intracellular domain is responsible for the protein's ability to interact with DNA and other intracellular structures.

DYNC2LI1 is a 21-kDa protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the DYNC family of proteins and is characterized by its ability to interact with other proteins on the same membrane and its intracellular domain.

One of the key features of DYNC2LI1 is its ability to interact with the protein known as DYNC2, which is also a member of the DYNC family of proteins. DYNC2 is a 23-kDa protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is characterized by its ability to interact with other proteins, including DYNC2LI1.

Research has shown that DYNC2LI1 and DYNC2 can interact with each other and with other proteins in a process that is involved in the regulation of cell-cell adhesion and migration. These interactions may play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its role in cell-cell adhesion and migration, DYNC2LI1 is also involved in the regulation of several other processes in the body. For example, it is known to be involved in the regulation of cell proliferation, differentiation, and survival. It is also involved in the regulation of inflammation and immune responses.

DYNC2LI1 is also a potential biomarker for several diseases, including cancer. Because it is involved in the regulation of cell-cell adhesion and migration, it may be useful as a biomarker for the development and progression of cancer. It is also involved in the regulation of cell proliferation, which may be useful as a biomarker for the effectiveness of anti-cancer drugs.

In conclusion, DYNC2LI1 is a unique protein that is involved in several important processes in the body. Its ability to interact with other proteins in the DYNC family and its involvement in the regulation of cell-cell adhesion and migration, as well as its potential as a biomarker for cancer and other diseases, make it an interesting target for further research. Further studies are needed to fully understand the role of DYNC2LI1 in the regulation of cell-cell adhesion and migration, as well as its potential as a biomarker for cancer and other diseases.

Protein Name: Dynein Cytoplasmic 2 Light Intermediate Chain 1

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the intraflagellar transport (IFT) system, facilitating the assembly of these organelles (PubMed:29742051). Involved in the regulation of ciliary length (PubMed:26077881, PubMed:26130459)

The "DYNC2LI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNC2LI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets